CD7 CAR T-cell

CD7 CAR T-cell therapy is an investigational cellular immunotherapy designed to treat relapsed or refractory (R/R) CD7-positive hematologic malignancies. It involves genetically engineering T-cells to express a chimeric antigen receptor (CAR) that specifically targets the CD7 protein found on malignant cells. This therapy is being evaluated in an "all-in-one" approach where it is sequentially followed by haploidentical hematopoietic stem cell transplantation (haplo-HSCT) without pharmacologic myeloablation or graft-versus-host disease (GVHD) prophylaxis. The therapy aims to induce remission and potentially durable disease control in patients with conditions such as acute myeloid leukemia, T-lymphoblastic lymphoma, and T-cell acute lymphoblastic leukemia.